AI Article Synopsis
- The study investigates the relationship between liver fibrosis and reactive oxygen species (ROS) levels produced by neutrophils, focusing on how this varies with age and sex in the general population.
- It involved 1,000 participants categorized into four groups based on sex and age, using various indices to assess liver fibrosis.
- Findings indicated positive correlations between liver fibrosis scores and basal ROS levels in younger participants, while in females, higher liver fibrosis scores were associated with lower stimulated ROS levels, suggesting that enhancing neutrophil function could help prevent liver-related diseases.
Article Abstract
Fibrosis, induced by reactive oxygen species (ROS) production in neutrophils, has harmful effects on the liver and various other organs. However, little is known about the association between liver fibrosis and ROS levels in neutrophils in the general population. This large-scale epidemiological study aimed to determine the association between liver fibrosis and neutrophil-generated ROS levels according to age and sex in the general population. This cross-sectional study included 1,000 participants from a district health promotion project. Participants were grouped based on sex (male; female) and age (young, <65 years; old, ≥65 years). The four groups were as follows: male, young ( = 289); male, old ( = 100); female, young ( = 425); and female, old ( = 186). Liver fibrosis was assessed using the fibrosis 4 (FIB-4) index, aspartate aminotransferase-to-platelet ratio index (APRI), and non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS). Basal and stimulated ROS were considered in the analysis. Multiple linear analyses showed (1) significant positive correlations between all liver fibrosis scores and basal ROS in the young groups, and (2) significant negative correlations between NFS and stimulated ROS in females. Preventing liver fibrosis through neutrophil-related immune system enhancement may avert the development of lifestyle-related diseases and infections.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636577 | PMC |
| http://dx.doi.org/10.3164/jcbn.23-46 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Local tissue response to a C-X-C motif chemokine ligand 12 therapy for fecal incontinence in a rabbit model.
Am J Physiol Gastrointest Liver Physiol
January 2025
Wake Forest Institute for Regenerative Medicine, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, USA.
This study aimed to determine if local injection of CXCL12 reduces sphincter fibrosis, restores sphincter muscle content, vascularization, and innervation, and recruits progenitor cells in a rabbit model of anal sphincter injury and incontinence. Adult female rabbits were assigned to 3 groups: uninjured/no treatment (control), injured/treated (treated), and injured/no treatment (untreated) (n=4 each). Injured groups were anesthetized and a section of external anal sphincter was removed at the 9:00 o'clock position.
View Article and Find Full Text PDFLubiprostone Reduces Fat Content on MRI-PDFF in Patients With MASLD: A 48-Week Randomised Controlled Trial.
Aliment Pharmacol Ther
January 2025
Liver Unit, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
Background And Aims: The laxative lubiprostone has been shown to decrease intestinal permeability. We aimed to assess the safety and efficacy of lubiprostone administered for 48 weeks in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
Approach And Results: A randomised placebo-controlled trial was conducted in a specialised MASLD outpatient clinic at the National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
The Proteomics of MASLD Progression: Insights From Functional Analysis to Drive the Development of New Therapeutic Solutions.
Aliment Pharmacol Ther
January 2025
Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading chronic liver disease worldwide, with alarming prevalence reaching epidemic proportions.
Aims And Methods: The objective of this study is to provide a comprehensive review of the latest blood proteomics studies on MASLD and metabolic dysfunction-associated steatohepatitis (MASH), with emphasis on fibrosis. Furthermore, our objective is to conduct an analysis of protein pathways and interactions by integrating proteomics data using functional enrichment analysis of the deregulated proteins.
Revisiting septic shock in cirrhosis: a call for personalized management.
Expert Rev Gastroenterol Hepatol
January 2025
Department of Hepatology, Institute of liver and biliary sciences, Delhi, India.
Introduction: Patients with cirrhosis are known to be prone to infections. Infections can trigger organ failures and decompensations in cirrhosis. Septic shock can increase mortality by fourfold and cause hemodynamic imbalances, adding to the already hyperdynamic circulation.
View Article and Find Full Text PDFIntroduction: Primary sclerosing cholangitis (PSC) is a biliary disorder associated with a high risk of end-stage liver disease and cholangiocarcinoma (CCA). Currently prediction of the unfavorable outcomes is hindered by the lack of valuable prognostic biomarkers.
Objectives: The aim of the study was to assess the prevalence of the autoantibodies in PSC and define their potential use as the predictors of progressive disease and CCA in a large, prospective cohort of PSC patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!